Vaccination following spinal cord injury: Innovative Weizmann Institute approach limits paralysis

New York, NY, August 17, 2001--Weizmann Institute scientists have proposed an innovative approach for preventing complete paralysis after partial spinal cord injury. The approach consists of boosting the body's natural immune mechanisms to improve the outcome of trauma.

The team of Prof. Michal Schwartz of the Weizmann Institute's Neurobiology Department has in the past already developed one immune-based therapy for the spinal cord, currently being tested in humans by Proneuron Biotechnologies Ltd. That therapy is aimed at repairing the spinal cord after a complete injury. The new approach pursues a related but different therapeutic target: to limit degeneration after a partial spinal cord injury. The scientists report their latest results in the August 15 issue of the Journal of Clinical Investigation.

Following injury to the central nervous system (brain or spinal cord), a wave of damage spreads from the injury site over several days or weeks, killing nerve cells and fibers that survived the initial trauma. This secondary degeneration can be even more destructive than the initial damage. As a result, an injury that initially inflicted only partial damage on the nerve tissue in the spinal cord may eventually result in total paralysis.

In the United States alone, approximately 10,000 people sustain a spinal cord injury each year. More than half of these injuries are classified as incomplete, or partial, meaning that some nerve fibers survived the initial trauma. If the surviving tissue could be protected against secondary degeneration, this would significantly improve the final outcome.

In the past, Schwartz and colleagues showed that autoimmune T cells -- the white blood cells of the immune system that interact with the body's own tissues -- have a protective effect on damaged tissue in the spinal cord, reducing secondary degeneration. This protective response is the body's own way of minimizing the consequences of trauma. How

Contact: Jeffrey Sussman
American Committee for the Weizmann Institute of Science

Page: 1 2

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Putting GPS to work, researchers shed light on road-following by pigeons
3. Tamoxifen stimulates breast cancer growth following alteration of estrogen receptor
4. Leave land alone following natural disasters, say researchers
5. Complement inhibitor decreases heart attacks and death in men following cardiac surgery
6. Researchers learn certain enzyme inhibitors may help in cancer therapy following initial procedures
7. Gene more than doubles risk of depression following life stresses
8. Dyslexic children`s brains operate more like those of normal readers following training
9. A new study sheds light on how the tongue restores its ability to taste following surgery
10. Life expectancy following diagnosis of Alzheimers disease depends on age at diagnosis
11. Hopkins researchers find postoperative fevers common following hemispherectomy

Post Your Comments:

(Date:8/5/2020)... (PRWEB) , ... August 05, 2020 , ... Regenative Labs ... two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to ... using a syringe. The company’s solutions are the first Wharton’s jelly allograft product to ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has ... Invictus Medical Neoasis™ active noise control device to attenuate typical noises in a ... device attenuated the alarm sounds from patient monitors, ventilators and other bedside devices ...
(Date:7/2/2020)... ... July 01, 2020 , ... ... phase 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute ... Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... N.J (PRWEB) , ... July 29, 2020 , ... ... company, and Catalent, the leading global provider of advanced delivery technologies, development, and ... today announced that they have entered into a strategic partnership whereby Catalent will ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... After research ... The completion of a great surgery is only the beginning of a successful study, ... research community. , Join Brad Gien, Global Head of Surgery from Envigo ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... that Massachusetts Institute of Technology (MIT) has expanded the company’s exclusive license ... to move into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 ...
(Date:7/1/2020)... , ... June 29, 2020 , ... ... to date growth of 40% in 2020, despite many obstacles created as a ... aims to increase revenue for its partnered medical practices and medical manufacturers by ...
Breaking Biology Technology:
Cached News: